OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
| Autor: | Sohn, Joohyuk, Pistilli, Barbara, Bellet, Meritxell, Del Mastro, Lucia, McArthur, Heather L., Meisel, Jane Lowe, Schmid, Peter, Wei, Rachel, Chan, Arlene, de Kermadec, Elisabeth |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement, Vol. 42, pTPS22-TPS22, 19p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|